---
title: Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Airways Disease
nct_id: NCT02238132
overall_status: COMPLETED
sponsor: Boehringer Ingelheim
study_type: OBSERVATIONAL
primary_condition: Pulmonary Disease, Chronic Obstructive
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02238132.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02238132"
ct_last_update_post_date: 2014-09-12
last_seen_at: "2026-05-12T06:37:12.613Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Airways Disease

**Official Title:** Postmarketing Surveillance Study (as Per §67(6)AMG[German Drug Law]) of Atrovent® Inhalets in Chronic Obstructive Airways Disease

**NCT ID:** [NCT02238132](https://clinicaltrials.gov/study/NCT02238132)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 374
- **Lead Sponsor:** Boehringer Ingelheim
- **Conditions:** Pulmonary Disease, Chronic Obstructive
- **Start Date:** 1998-12
- **CT.gov Last Update:** 2014-09-12

## Brief Summary

To obtain further information on the tolerability of Atrovent® inhalets in the treatment of Chronic Obstructive Airways Disease under conditions of daily practice

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Primarily, Patients with chronic obstructive airways disease
* Only patients who had not been treated with Atrovent® in the last year were to be considered for inclusion

Exclusion Criteria:

\- Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Atrovent® inhalets
```

## Arms

- **Chronic Obstructive Airways Disease**

## Interventions

- **ATROVENT® inhalets** (DRUG)

## Primary Outcomes

- **Investigator assessment of improvement in the clinical picture of the course on a 6-point symptoms profile** _(time frame: Up to 4 weeks after first study drug administration)_

## Secondary Outcomes

- **Investigator assessment of efficacy on a 4-point scale** _(time frame: Up to 4 weeks after first study drug administration)_
- **Investigator assessment of tolerability on a 4-point scale** _(time frame: Up to 4 weeks after first study drug administration)_
- **Number of patients with adverse drug reactions** _(time frame: Up to 4 weeks after first study drug administration)_
- **Number of patients who withdrew from the study** _(time frame: Up to 4 weeks after first study drug administration)_
- **Number of patients who changed the concomitant medication** _(time frame: Up to 4 weeks after first study drug administration)_
- **Number of patients who continued the treatment** _(time frame: Up to 4 weeks after first study drug administration)_
- **Patient assessment of efficacy on a 4-point scale** _(time frame: Up to 4 weeks after first study drug administration)_
- **Patient assessment of tolerability on a 4-point scale** _(time frame: Up to 4 weeks after first study drug administration)_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02238132.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02238132*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*